In this second part of TOGA's Conversations in Lung Cancer Research two-episode series, A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital, leads a panel discussing the clinical implications of the March 1st broad Pharmaceutical Benefits Scheme (PBS) listing of ipilimumab and nivolumab in Australia. Joined by Prof Nick Pavlakis (Senior Staff Specialist at Royal North Shore Hospital, Professor of Medicine at the University of Sydney, former chair of TOGA), Dr. Sam Bowyer (Medical Oncologist at Sir Charles Gairdner Hospital and Clinical Researcher at Linear Clinical Research) and Dr. Lavinia Tan (Medical Oncologist at Peter MacCallum Cancer Centre), the conversation explores how this newly granted flexibility alters treatment paradigms across various thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, small cell lung cancer (SCLC), and rare thymic tumours while also addressing toxicity management and the growing demands of patient survivorship.
In this second part of TOGA's Conversations in Lung Cancer Research two-episode series, A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital, leads a panel discussing the clinical implications of the March 1st broad Pharmaceutical Benefits Scheme (PBS) listing of ipilimumab and nivolumab in Australia. Joined by Prof Nick Pavlakis (Senior Staff Specialist at Royal North Shore Hospital, Professor of Medicine at the University of Sydney, former chair of TOGA), Dr. Sam Bowyer (Medical Oncologist at Sir Charles Gairdner Hospital and Clinical Researcher at Linear Clinical Research) and Dr. Lavinia Tan (Medical Oncologist at Peter MacCallum Cancer Centre), the conversation explores how this newly granted flexibility alters treatment paradigms across various thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, small cell lung cancer (SCLC), and rare thymic tumours while also addressing toxicity management and the growing demands of patient survivorship.
Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers.
(00:00) Welcome and Acknowledgement
(01:33) Panel Introductions
(02:52) First Reactions in Clinic
(05:01) Frontline NSCLC Evidence
(06:48) Who Gets Ipi Nivo?
(11:29) Chemo Free and Rechallenge
(15:20) Stopping or Continuing IO
(20:34) Mesothelioma Treatment Choices
(27:20) Small Cell Reality Check
(30:21) Thymic Malignancies Debate
(34:54) Governance and Toxicity Safety
(38:44) Survivorship and Follow Up
(43:43) Real World Data Next Steps
(48:05) Wrap Up